anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The endogenous neuromodulator adenosine is massively released during hypoxic/ischemic insults and differentially modulates post-ischemic damage depending on the expression and recruitment of its four metabotropic receptor subtypes, namely A1, A2A, A2B and A3 receptors (A1Rs, A2ARs, A2BRs and A3Rs). We previously demonstrated, by using a model of transient middle cerebral artery occlusion (tMCAo) in rats, that selective activation of A2ARs, as well as A2BRs, ameliorates post-ischemic brain damage in contrast to neuroinflammation. In the present study, we investigated whether the multitarget nucleoside MRS3997, a full agonist at both A2ARs and A2BRs, would afford higher neuroprotection in post-ischemic damage. Chronic systemic treatment with MRS3997 reduced neurological deficit, body weight loss and infarct volume in the cortex and striatum measured 7 days after ischemia. The dual agonist counteracted neuronal loss, reduced myelin damage, and prevented morphological changes indicative of microglia and astrocyte activation. Finally, MRS3997 shifted plasma cytokine levels to an anti-inflammatory profile. These effects were preceded, at 2 days after the insult, by a reduced granulocyte infiltration in the ischemic cortex and, differently from what was observed with selective A2AR or A2BR agonism, also in striatum. In summary, we demonstrate here that MRS3997, systemically administered for 7 days after tMCAO, protects ischemic areas from neuronal and glial damage and inhibits neuroinflammation, therefore representing an attractive strategy to ameliorate post-stroke damage and neurological symptoms.
PCT No. PCT/US94/13952 Sec. 371 Date Mar. 15, 1995 Sec. 102(e) Date Mar. 15, 1995 PCT Filed Dec. 6, 1994 PCT Pub. No. WO95/16039 PCT Pub. Date Jun. 15, 1995The present invention is directed to the identification of mutant strains of methicillin resistant bacteria, in particular methicillin resistant Staphylococcus aureus, to identify the characteristics of such bacteria and develop drugs that can reverse, inhibit or reduce bacterial resistance to beta lactam antibiotics, e.g., methicillin. The invention particularly relates to identification of a novel mutant strain of methicillin resistant S. aureus that manifests a unique phenotype. The mutant strain lacks unsubstituted pentapeptide and incorporates alanylglutamate- and alanylisoglutamine-containing muropeptides, and accumulates large amounts of the UDP-linked muramyul dipeptide in the cytoplasmic wall precursor pool of the mutant. Based on the phenotypic consequences of the mutation, inhibitors of the lysine addition step in bacterial cell wall biosyntheis are identified as having therapeutic potential for reducing bacterial resistance to beta lactam antibiotics, notably methicillin. Accordingly, the invention provides for methods of treatment and corresponding pharmaceutical compositions for treating bacterial, particularly staphylococcal, infections.
Sunscreen compositions comprising from about 0.5 % to about 30 % by weight of a metal oxide which is titanium dioxide, zinc oxide or a mixture of both these oxides and from about 0.001 % to about 2 % by weight of iron oxide particles having a mean primary particle size of less than about 200 nm are described. The metal oxide may be substantially in the form of particles having a mean primary particle size of less than about 100 nm. The preferred form of iron oxide is iron (III) oxide. Optionally, either the metal oxide or the iron oxide particles or both are coated with a phospholipid such as lecithin. The sunscreen compositions may include phosphate anions. Sunscreen compositions comprising the above ingredients in both oil-in-water and water-in-oil emulsions are also disclosed.
<P>PROBLEM TO BE SOLVED: To provide a chimera peptides for promoting the transportation of insulin through a bio-membrane, its composition, a method for producing the chimera peptides and a method for treating diabetes mellitus patients.  <P>SOLUTION: This chimera peptide having a first domain and second domain is provided. The first domain is a translocation sequence for promoting the active transportation across the bio-membrane and the second domain is at least a part of the insulin peptide. Also, the chimera peptide can perform the translocation of the bio-membrane such as a plasma membrane, mitochondria membrane, nuclear membrane or the like. Also the chimera peptide can perform the translocation of physiological barriers such as a gastroenteric barrier, blood brain barrier, skin barrier, respiratory epithelium barrier, through cellular membrane barrier, nose barrier, eye barrier, etc.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention discloses a recombinant human II type mitochondrial dynamic protein-like GTP enzyme gene sequence and application thereof, wherein the nucleotide sequence is shown as SEQ ID NO. 1. Also disclosed is a fusion nucleic acid comprising the nucleic acid encoding human type II mitochondrial dynein-like GTPase. Further disclosed is a recombinant expression vector comprising the above nucleic acid or fusion nucleic acid. Also disclosed is a transformant which has the above-mentioned nucleic acid or fused nucleic acid introduced into a host. The nucleic acid for coding the human II type mitochondrial dynein-like GTPase has higher expression level, so that more human II type mitochondrial dynein-like GTPases can be obtained from mitochondria, and the eye diseases such as ADOA and the like can be better treated.
Children with CP will watch the video on the computer screen placed 1 m in front of a chair in which they can sit comfortably, but they will not be allowed to move while watching the video. The therapist will explain the exercises verbally. Children will practice the exercise after watching cartoons. The watching time for each exercise is 3 minutes, and after watching 3 minutes of cartoons, they will do the exercise for 3 minutes. Children will be instructed to concentrate on the video at 1-minute intervals to allow children's attention span. The treatment program will be applied for 30 minutes, 5 days a week for 3 weeks. The first session of the exercise program will be held face-to-face and the other sessions will be followed online. Treatment will be started within the first 48 hours after the evaluation. After the applications, pre-treatment evaluations will be repeated.
The utility model involved is disclosed as an anti-inflammatory liniment for topical application. Lagundi, Vitex negundo, leaves ethanolic extract is the active ingredient of the formulation. Lagundi leaves were extracted using exhaustive extraction through Soxhlet apparatus. It was then concentrated into a syrupy consistency in vacuum using rotary evaporator. The product obtained is now the lagundi leaves extract. The extract was subjected to a protein stabilization test to determine its anti-inflammatory action. The result concluded that the extract indeed has anti-inflammatory property. The liniment base used may consist of two vehicles: alcoholic and oil based formulation. The alcoholic base consists of propylene glycol 30-50 pcnt v/v, ethanol 30-50 pcnt v/v, and menthol 2-10 pcnt w/v. While the oil based formulation consists of 70-80 pcnt cottonseed oil, 15- 25 pcnt propylene glycol, and 23-27 pcnt lagundi extract. The formulated liniment was subjected to scratch and patch test to determine its safety profile. The result concludes that it is safe to apply to the skin because it will not cause irritation.
FIELD: biotechnology, microbiology. SUBSTANCE: strains of Streptomyces avermitilis that do not show activity of 2-oxo-acid branched chain dehydrogenase and amino acid branched chain transaminase were used for producing natural and unnatural avermectins with the certain value of radical R. Strains Str. avermitilis were deposited in ATCC and have the collection numbers ATCC N 53567, N 53568, N 53669 and N 53670. The produced avermectins show strong antiparasitic activity. EFFECT: improved method of producing. 12 cl, 3 dwg , 4 tbl
Three-dimensional information is essential for a proper understanding of the healing potential of the menisci and their overall role in the knee joint. However, to date, the study of meniscal vascularity has relied primarily on two-dimensional imaging techniques. Here we present a method to elucidate the intricate 3D meniscal vascular network, revealing its spatial arrangement, connectivity and density. A polymerizing contrast agent was injected into the femoral artery of human cadaver legs, and the meniscal microvasculature was examined using micro-computed tomography at different levels of detail and resolution. The 3D vascular network was quantitatively assessed in a zone-base analysis using parameters such as diameter, length, tortuosity, and branching patterns. The results of this study revealed distinct vascular patterns within the meniscus, with the highest vascular volume found in the outer perimeniscal zone. Variations in vascular parameters were found between the different circumferential and radial meniscal zones. Moreover, through state-of-the-art 3D visualization using micro-CT, this study highlighted the importance of spatial resolution in accurately characterizing the vascular network. These findings, both from this study and from future research using this technique, improve our understanding of microvascular distribution, which may lead to improved therapeutic strategies.
The expected signs and symptoms associated with overdosage of arformoterol tartrate inhalation solution are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms listed under ADVERSE REACTIONS. 

Signs and symptoms may include angina, hypertension or hypotension, tachycardia, with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of arformoterol tartrate inhalation solution.

Treatment of overdosage consists of discontinuation of arformoterol tartrate inhalation solution together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of arformoterol tartrate inhalation solution. Cardiac monitoring is recommended in cases of overdosage.
The present invention relates to a toothpaste composition containing a Perilla frutescens herbal medicinal material extract. More specifically, the toothpaste composition comprises an abrasive, a wetting agent, and purified water and further comprises a Perilla frutescens herbal medicinal material extract. The Perilla frutescens herbal medicinal material extract comprises white Atractylis, Scutellaria baicalensis Georgi, Japanese Angelica, Paeonia japonica, Rehmannia glutinosa, Amomum seeds, dried orange peel, Cnidium officinale Makino, and Perilla ocymoides. According to the toothpaste composition of the present invention, the use of a synthetic detergent, a synthetic fragrance, a synthetic preservative, or the like is excluded, and the concentration of fluorine is lowered. Thus, the composition is not harmful to a human body, is not irritating, and has excellent effects of preventing and treating periodontal diseases. In addition, when the composition is used by a pregnant person, both the oral health and the whole body health are enhanced. Thus, healthy birth of the fetus can be helped.
A tracking system for quantifying retinal traction on a retina of a patient eye includes an indicator device, a stereo camera, and an electronic control unit (ECU). The stereo camera collects and outputs stereo image data. The ECU, which is in communication with the indicator device, executes a method by receiving the stereo image data from the stereo camera during an ophthalmic procedure and thereafter assigning tracking points as coinciding pixels within stereo image pairs. The ECU also automatically performs a digital image correlation (DIC) process using the stereo image pairs to ascertain relative motion of the tracking points, and associates relative motion of the tracking points with the retinal traction using a traction map. A numeric traction quotient is generated that is indicative of magnitude of retinal traction. The ECU executes a control action using the indicator device based on the numeric traction quotient.
The present invention allows clinical trial organizers to operate a platform for creating trial specific custom mobile applications at a price point that would not be possible if the application were created by programmers on a trial-by-trial basis. The invention shortens build time by creating a hierarchy of questions that changes the next question posed to the user based upon their answer to a previous question thereby reducing the number of questions the user must answer while providing the application creation platform with the detailed information relevant to a specific clinical trial. The platform uses a simulation builder that provides a test version of the application to the user mobile device during the application creation process thereby allowing the user to see the layout of the application as they progress through the building process. While building the application, the user can create a simulated version of the application in real time deliver the same to the mobile device of the user. The system creates a handshaking process that allows the user to create annotations and/or edits in the simulated application that are communicated back to the building platform. Changes made in the simulated application will affect the landing page the user sees when returning to the building platform. The system will collect usability data from a clinical trial application on a plurality of trial subject and trial organizer mobile devices. The system can measure variables such as time on page, misentries, and missed selections of icons to determine common trouble spots for users. That data may be used to redesign the interface or process flow of the application to optimize usability
Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
FIELD: medicine. SUBSTANCE: plasma is placed into plastic container and disposed its between two metallic plates. Then this plasma is subjected for successive stages of freezing, storage and defrosting. Process of plasma freezing is carried out at the rate 2-3 C/s, defrosting - at the rate 1.5-2 C/s up to onset of thawing followed by plasma heating at 37 C. Method ensures to retain up to 98% of functionally active platelets. EFFECT: improved method of plasma cryoconservation. 1 cl, 2 tbl, 1 ex
The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
OBJECTIVES: This study aims to compare the efficacy of remote versus in-person training strategies to teach ultrasound guided knee arthrocentesis using formalin embalmed cadavers.
METHODS: 30 first-year medical student participants were randomly assigned to remote or in-person training groups. Pre- and post- training surveys were used to evaluate participant's self-confidence in their ability to perform the procedure. Participants were asked to watch a 30-minute training video and then attend a skills training workshop. The workshops consisted of 20 min of hands-on instruction followed by a skills assessment.
RESULTS: Following training, participant self-confidence increased significantly across all survey items in both groups (p = 0.0001). No significant changes in participant self-confidence were detected between the groups. Skills and knowledge-related metrics did not differ significantly between the groups with the exception of the "knowledge of instruments" variable.
CONCLUSIONS: Our data suggests that remote ultrasound-guided procedure training, although logistically complex, is a viable alternative to traditional in-person learning techniques even for a notoriously hands on skill like ultrasound guided knee arthrocentesis. Novice first-year medical student operators in the remote-training group were able to significantly increase their confidence and demonstrate competency in a manner statistically indistinguishable from those trained in-person. These results support the pedagogical validity of using remote training to teach ultrasound guided procedures which could have implications in rural and global health initiatives where educational resources are more limited.
The invention discloses a traditional Chinese medicine pill of a pill for securing essence and tonifying kidney, which is prepared from the following components in part by weight: the invention relates to a Chinese medicinal composition for tonifying kidney and replenishing essence, astringing and gathering essence, strengthening tendons and bones, harmonizing stomach and invigorating spleen, supplementing qi and blood, restoring kidney qi, tonifying congenital, benefiting acquired, securing essence and replenishing marrow, which is prepared from 12 Chinese medicaments such as common yam rhizome, walnut meat, astragalus, Chinese angelica, lotus stamen, cherokee rose fruit, gordon euryale seed, prepared rhizome of rehmannia, tortoise plastron, lotus seed, flatstem milkvetch seed, Chinese date peel and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating physiological function of kidney, invigorating kidney, replenishing essence, astringing, strengthening muscle and bone, regulating stomach function, invigorating spleen, invigorating qi and blood, restoring kidney qi, invigorating congenital qi, invigorating postnatal qi, arresting spontaneous emission, and replenishing marrow. 4. Can improve symptoms and signs of patients with kidney qi deficiency, essence discharge, white turbidity, kidney deficiency and edema chronic diseases, astringe and tonify essence, and strengthen kidney.
Certain cancer cells within solid tumors experience hypoxia, rendering them incapable of oxidative phosphorylation (OXPHOS). Despite this oxygen deficiency, these cells exhibit biochemical pathway activity that relies on NAD+. This mini-review scrutinizes the persistent, residual Complex I activity that oxidizes NADH in the absence of oxygen as the electron acceptor. The resulting NAD+ assumes a pivotal role in fueling the α-ketoglutarate dehydrogenase complex, a critical component in the oxidative decarboxylation branch of glutaminolysis - a hallmark oncometabolic pathway. The proposition is that through glutamine catabolism, high-energy phosphate intermediates are produced via substrate-level phosphorylation in the mitochondrial matrix substantiated by succinyl-CoA ligase, partially compensating for an OXPHOS deficiency. These insights provide a rationale for exploring Complex I inhibitors in cancer treatment, even when OXPHOS functionality is already compromised.
In an academic pediatric Emergency Depratment (ED), we performed a randomized clinical trial of children \< 7 years of age, who required i.v. access and who had failed the first i.v. attempt. We randomized patients to either continued standard i.v. attempts or ultrasound-assisted attempts. Clinicians involved in the study received one hour of training in ultrasound localization of peripheral veins. In the ultrasound group, vein localization was performed by an ED physician who marked the skin overlying the target vessel. Intravenous cannulation attempts were then immediately performed by a pediatric ED nurse who relied on the skin mark for vessel location. We allowed for technique cross-over after two failed i.v. attempts. We recorded success rate and location of access attempts.
Overweight/Obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
This observational study is investigating a simple test of walking speed, measured using the 4 metre gait speed test (4MGS), in patients with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). Drug development for this disease is slow in part because there is a lack of reliable measurements that can assess effectiveness of treatment. Slow walking speed has been shown to relate to poor outcomes in older adults and people with another lung disease called Chronic Obstructive Pulmonary Disease (COPD. The investigators are interested to see whether usual walking speed is a reliable measure in patients with IPF as this will help inform us of its potential use as an outcome measure. To do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet). Participants will be asked to do this twice with a rest in between if required. One week later, participants will be asked to repeat the walking tests again.
PURPOSE:To obtain the subject composition having enhanced preventive effects on adsorption of a water-soluble physiologically active polypeptide on containers, injection syringes, etc., by the presence of the aforementioned polypeptide in an aqueous phase of an oil-in-water type emulsion formed at least fats and oils, an emulsifying agent and an adequate amount of water. CONSTITUTION:The subject composition, obtained by the presence of a water-soluble physiologically active polypeptide having preferably 1000-300000 molecular weight in an aqueous phase of an oil-in-water emulsion, formed from at least fats and oils, an emulsifying agent and an adequate amount of water and having preferably 0.05-0.5mum particle diameter of emulsion particles, capable of enhancing adsorption preventive power of the emulsifying agent, such as a phospholipid, having weak adsorption preventive power alone by using the fats and oils in combination and sufficient adsorption preventive effects with a small amount thereof and reducing adsorption loss to <=20%, especially <=10% even in drip infusion and excellent also in stability and safety for a long period. Furthermore, the ingredients are preferably used in the following amounts. 0.0001-20% fats and oils in the aforementioned composition and the emulsifying agent in an amount of 5-20 pts. based on 100 pts. fats and oils.